资讯
British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...
London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...
Moderna 首席执行官 Stéphane Bancel 在新闻稿中表示:“FDA 批准我们的第二款 [RSV] 产品 mRESVIA,这建立在我们 mRNA 平台的优势和多功能性之上。”“mRESVIA 可保护老年人免受 RSV 感染的严重后果,它是唯一一种采用预填充注射器的 RSV 疫苗,旨在最大限度地提高给药的便利性,节省接种者的时间并降低管理错误的风险。” ...
GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...
2 天
Zacks.com on MSNFDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger AdultsArexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59.
3 天
GlobalData on MSNGSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patientsThe label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...
The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...
Phase 3 clinical trial data showed the GSK vaccine had an efficacy of 82.6% in preventing confirmed lower respiratory tract disease caused by RSV. The vaccine includes an adjuvant, a compound that ...
The Wednesday approval of the GSK vaccine, known in development as RSVPreF3 OA, covers the prevention of RSV infection in adults age 60 and older. GSK will market its new product under the brand ...
GSK’s vaccines rouse the body’s immunity with an RSV surface protein called the F glycoprotein. Before the virus breaks in and enters the host cell, it exists in a lollipop-shaped prefusion form .
GSK said that its vaccine against RSV reduced the risk of developing lower respiratory tract disease by 82.6% in a large trial. Photo: kenzo tribouillard/Agence France-Presse/Getty Images ...
GSK does not expect initial uptake of its RSV vaccine will be as swift as it was for its blockbuster shingles vaccine, though the company is confident in its new inoculation, Chief Executive Emma ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果